|Indication||Discovery||in vivo POC||pre-IND||Phase I|
|Type 1 Diabetes||
Topas is utilizing its cutting-edge technology platform to develop a pipeline of novel therapies to treat autoimmune diseases, allergies and anti-drug antibodies.
- Pemphigus vulgaris (PV): PV, an orphan disease, is an autoimmune condition where there is painful blistering on the skin and mucous membranes. While treatments are available to manage the condition, there is no cure. For this indication, there is already extensive knowledge about the related antigen, a validated biomarker and a clear and fast clinical phenotype (observable characteristics). Thus, it is an ideal area to demonstrate clinical proof-of-concept for the Topas Particle Conjugates (TPC) technology. The program is expected to enter the clinic in 2019.
- ADA-1: Topas is exploring a model system to prove successful projection of its approach towards the prevention of neutralizing antibodies generated against a marketed therapeutic. The program’s initial goal is to achieve pre-clinical proof-of-concept.
- Type 1 diabetes: This program is initially focused on achieving pre-clinical proof-of-concept. Should this program be successful, it would support the ability of the Topas platform to also regulate cytotoxic CD8+ T-cells. Type 1 diabetes represents an attractive commercial opportunity as there remains a need for treatments that are disease modifying and are more convenient and comfortable for patients, who are often children.
- Celiac disease: Patients with celiac disease must avoid a wide variety of foods or suffer often severe stomach pain. Gluten is a well-described external antigen, making this a good area of focus for the TPC technology. The initial goal of this program is to achieve pre-clinical proof-of-concept.
- Multiple sclerosis (MS): Despite significant progress in finding new, more effective treatments for MS, there remains a need to find causative therapies that are more effective, convenient and comfortable for patients. The Topas program comprises a number of TPCs representing several MS antigens. Early pre-clinical results demonstrated that, in an autoimmune encephalomyelitis model (common model to represent MS), all mice were fully protected from developing MS by a one-time injection of an MS-relevant TPC. The MS program will be developed further with a partner.